BeiGene Ltd (BGNE) is a biopharmaceutical company that develops and markets innovative medicines to treat cancer and other life-threatening diseases. The company has a focus on immuno-oncology and is dedicated to discovering and developing novel drugs that harness the power of the immune system to fight cancer. BeiGene has a number of clinical and pre-clinical stage programs underway, including those targeting solid tumors, hematological malignancies, and other areas of high unmet need. The company is headquartered in Beijing, China, and has offices in the United States, Europe, and Asia. BeiGene has collaborations with a number of leading pharmaceutical companies and academic institutions around the world, and is committed to making a meaningful difference in the lives of patients with cancer.
BeiGene Ltd (BGNE) is a biopharmaceutical company that develops and markets innovative medicines to treat cancer and other life-threatening diseases. The company has a focus on immuno-oncology and is dedicated to discovering and developing novel drugs that harness the power of the immune system to fight cancer. BeiGene has a number of clinical and pre-clinical stage programs underway, including those targeting solid tumors, hematological malignancies, and other areas of high unmet need. The company is headquartered in Beijing, China, and has offices in the United States, Europe, and Asia. BeiGene has collaborations with a number of leading pharmaceutical companies and academic institutions around the world, and is committed to making a meaningful difference in the lives of patients with cancer.